Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers: Integrated Analysis of Intravenous and Subcutaneous, Single- and Multiple-Dose Administration

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial

(2013) Ralf Gold et al.   LANCET

Inhibition of LTi Cell Development by CD25 Blockade Is Associated with Decreased Intrathecal Inflammation in Multiple Sclerosis

(2012) J. S. A. Perry et al.   Science Translational Medicine

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta

(2010) Daniel Wynn et al.   LANCET NEUROLOGY

The immunogenetics of multiple sclerosis

(2008) Arne Svejgaard   IMMUNOGENETICS

The Biology of Interleukin-2

(2007) Thomas R. Malek   Annual Review of Immunology

Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients

(2007) Mark D. Pescovitz et al.   PEDIATRIC TRANSPLANTATION